Shopping Cart 0
Cart Subtotal
USD 0

Alnylam Pharmaceuticals Inc (ALNY) - Financial and Strategic SWOT Analysis Review

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 125

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 250

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 375

Details

Alnylam Pharmaceuticals Inc (ALNY)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Alnylam Pharmaceuticals Inc (Alnylam) is a biopharmaceutical company which discovers, develops and commercializes therapeutics based on Ribo Nucleic Acid interference (RNAi). The company offers a broad pipeline of investigational RNAi therapeutics in the areas of genetic medicines, hepatic infectious diseases, cardio-metabolic diseases, and central nervous system (CNS) diseases. Its late stage product candidates include Patisiran for hereditary transthyretin-mediated (hATTR) amyloidosis, Inclisiran for hypercholesterolemia, Fitusiran for hemophilia and rare bleeding disorders and Givosiran for acute hepatic porphyrias. It operates subsidiaries in the US, Canada, France, Germany, Italy, Spain, Sweden, the Netherlands, Switzerland and the UK. Alnylam is headquartered in Cambridge, Massachusetts, the US.

Alnylam Pharmaceuticals Inc Key Recent Developments

Jun 20,2018: Alnylam Pharmaceuticals Announces Senior Management Changes

May 15,2018: Alnylam Appoints Colleen Reitan to the Board of Directors

May 08,2018: Alnylam Reports Preclinical Data Demonstrating Central Nervous System (CNS) Delivery of RNAi Therapeutics

May 03,2018: Alnylam Pharmaceuticals Reports First Quarter 2018 Financial Results and Highlights Recent Period Activity

Apr 20,2018: Dicerna Pharmaceuticals Announces Settlement of All Litigation with Alnylam

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

Alnylam Pharmaceuticals Inc-Key Facts 6

Alnylam Pharmaceuticals Inc-Key Employees 7

Alnylam Pharmaceuticals Inc-Key Employee Biographies 8

Alnylam Pharmaceuticals Inc-Major Products and Services 9

Alnylam Pharmaceuticals Inc-History 10

Alnylam Pharmaceuticals Inc-Company Statement 16

Alnylam Pharmaceuticals Inc-Locations And Subsidiaries 17

Head Office 17

Other Locations & Subsidiaries 17

Joint Venture 17

Section 2-Company Analysis 19

Company Overview 19

Alnylam Pharmaceuticals Inc-Business Description 20

Alnylam Pharmaceuticals Inc-Corporate Strategy 21

Alnylam Pharmaceuticals Inc-SWOT Analysis 22

SWOT Analysis-Overview 22

Alnylam Pharmaceuticals Inc-Strengths 22

Alnylam Pharmaceuticals Inc-Weaknesses 23

Alnylam Pharmaceuticals Inc-Opportunities 24

Alnylam Pharmaceuticals Inc-Threats 25

Alnylam Pharmaceuticals Inc-Key Competitors 26

Section 3-Company Financial Ratios 27

Financial Ratios-Capital Market Ratios 27

Financial Ratios-Annual Ratios 28

Performance Chart 30

Financial Performance 30

Financial Ratios-Interim Ratios 31

Financial Ratios-Ratio Charts 32

Section 4-Company's Lifesciences Financial Deals and Alliances 33

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 33

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 34

Alnylam Pharmaceuticals Inc, Recent Deals Summary 35

Section 5-Company's Recent Developments 36

May 15, 2018: Alnylam Appoints Colleen Reitan to the Board of Directors 36

May 08, 2018: Alnylam Reports Preclinical Data Demonstrating Central Nervous System (CNS) Delivery of RNAi Therapeutics 37

May 03, 2018: Alnylam Pharmaceuticals Reports First Quarter 2018 Financial Results and Highlights Recent Period Activity 38

Apr 20, 2018: Alnylam Reaches Settlement Agreement with Dicerna Pharmaceuticals Resolving Trade Secret Misappropriation and Other Pending Litigation 41

Apr 20, 2018: Dicerna Pharmaceuticals Announces Settlement of All Litigation with Alnylam 42

Mar 21, 2018: Regeneron Genetics Center Publication in New England Journal of Medicine Identifies New Genetic Variant Providing Protection from Chronic Liver Disease 43

Feb 08, 2018: Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Period Activity 45

Jan 10, 2018: Regeneron forms consortium to advance human gene sequencing 48

Jan 10, 2018: Regeneron forms consortium to advance human gene sequencing 49

Jan 07, 2018: Alnylam Announces 2018 Corporate Goals 50

Section 6-Appendix 52

Methodology 52

Ratio Definitions 52

About GlobalData 56

Contact Us 56

Disclaimer 56


List Of Figure

List of Figures

Alnylam Pharmaceuticals Inc, Performance Chart (2013-2017) 30

Alnylam Pharmaceuticals Inc, Ratio Charts 32

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 33

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 34


List Of Table

List of Tables

Alnylam Pharmaceuticals Inc, Key Facts 6

Alnylam Pharmaceuticals Inc, Key Employees 7

Alnylam Pharmaceuticals Inc, Key Employee Biographies 8

Alnylam Pharmaceuticals Inc, Major Products and Services 9

Alnylam Pharmaceuticals Inc, History 10

Alnylam Pharmaceuticals Inc, Subsidiaries 17

Alnylam Pharmaceuticals Inc, Joint Venture 17

Alnylam Pharmaceuticals Inc, Key Competitors 26

Alnylam Pharmaceuticals Inc, Ratios based on current share price 27

Alnylam Pharmaceuticals Inc, Annual Ratios 28

Alnylam Pharmaceuticals Inc, Annual Ratios (Cont...1) 29

Alnylam Pharmaceuticals Inc, Interim Ratios 31

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 33

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 34

Alnylam Pharmaceuticals Inc, Recent Deals Summary 35

Currency Codes 52

Capital Market Ratios 52

Equity Ratios 53

Profitability Ratios 53

Cost Ratios 54

Liquidity Ratios 54

Leverage Ratios 55

Efficiency Ratios 55

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Alnylam Pharmaceuticals Inc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Sylentis SAU

SOM Biotech SL

Quark Pharmaceuticals Inc

Prothena Corp Plc

Pfizer Inc

Marina Biotech Inc

Ionis Pharmaceuticals Inc

GlaxoSmithKline Plc

Dicerna Pharmaceuticals Inc

Arrowhead Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc (ALNY)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Alnylam Pharmaceuticals Inc (Alnylam) is a biopharmaceutical company which discovers, develops and commercializes therapeutics based on Ribo Nucleic Acid interference (RNAi). The company offers a broad pipeline of investigational RNAi therapeutics in the areas of genetic medicines, hepatic infectious diseases, cardio-metabolic diseases, and central nervous system (CNS) diseases. Its late stage product candidates include Patisiran for hereditary transthyretin-mediated (hATTR) amyloidosis, Inclisiran for hypercholesterolemia, Fitusiran for hemophilia and rare bleeding disorders and Givosiran for acute hepatic porphyrias. It operates subsidiaries in the US, Canada, France, Germany, Italy, Spain, Sweden, the Netherlands, Switzerland and the UK. Alnylam is headquartered in Cambridge, Massachusetts, the US.

Alnylam Pharmaceuticals Inc Key Recent Developments

Jun 20,2018: Alnylam Pharmaceuticals Announces Senior Management Changes

May 15,2018: Alnylam Appoints Colleen Reitan to the Board of Directors

May 08,2018: Alnylam Reports Preclinical Data Demonstrating Central Nervous System (CNS) Delivery of RNAi Therapeutics

May 03,2018: Alnylam Pharmaceuticals Reports First Quarter 2018 Financial Results and Highlights Recent Period Activity

Apr 20,2018: Dicerna Pharmaceuticals Announces Settlement of All Litigation with Alnylam

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

Alnylam Pharmaceuticals Inc-Key Facts 6

Alnylam Pharmaceuticals Inc-Key Employees 7

Alnylam Pharmaceuticals Inc-Key Employee Biographies 8

Alnylam Pharmaceuticals Inc-Major Products and Services 9

Alnylam Pharmaceuticals Inc-History 10

Alnylam Pharmaceuticals Inc-Company Statement 16

Alnylam Pharmaceuticals Inc-Locations And Subsidiaries 17

Head Office 17

Other Locations & Subsidiaries 17

Joint Venture 17

Section 2-Company Analysis 19

Company Overview 19

Alnylam Pharmaceuticals Inc-Business Description 20

Alnylam Pharmaceuticals Inc-Corporate Strategy 21

Alnylam Pharmaceuticals Inc-SWOT Analysis 22

SWOT Analysis-Overview 22

Alnylam Pharmaceuticals Inc-Strengths 22

Alnylam Pharmaceuticals Inc-Weaknesses 23

Alnylam Pharmaceuticals Inc-Opportunities 24

Alnylam Pharmaceuticals Inc-Threats 25

Alnylam Pharmaceuticals Inc-Key Competitors 26

Section 3-Company Financial Ratios 27

Financial Ratios-Capital Market Ratios 27

Financial Ratios-Annual Ratios 28

Performance Chart 30

Financial Performance 30

Financial Ratios-Interim Ratios 31

Financial Ratios-Ratio Charts 32

Section 4-Company's Lifesciences Financial Deals and Alliances 33

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 33

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 34

Alnylam Pharmaceuticals Inc, Recent Deals Summary 35

Section 5-Company's Recent Developments 36

May 15, 2018: Alnylam Appoints Colleen Reitan to the Board of Directors 36

May 08, 2018: Alnylam Reports Preclinical Data Demonstrating Central Nervous System (CNS) Delivery of RNAi Therapeutics 37

May 03, 2018: Alnylam Pharmaceuticals Reports First Quarter 2018 Financial Results and Highlights Recent Period Activity 38

Apr 20, 2018: Alnylam Reaches Settlement Agreement with Dicerna Pharmaceuticals Resolving Trade Secret Misappropriation and Other Pending Litigation 41

Apr 20, 2018: Dicerna Pharmaceuticals Announces Settlement of All Litigation with Alnylam 42

Mar 21, 2018: Regeneron Genetics Center Publication in New England Journal of Medicine Identifies New Genetic Variant Providing Protection from Chronic Liver Disease 43

Feb 08, 2018: Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Period Activity 45

Jan 10, 2018: Regeneron forms consortium to advance human gene sequencing 48

Jan 10, 2018: Regeneron forms consortium to advance human gene sequencing 49

Jan 07, 2018: Alnylam Announces 2018 Corporate Goals 50

Section 6-Appendix 52

Methodology 52

Ratio Definitions 52

About GlobalData 56

Contact Us 56

Disclaimer 56


List Of Figure

List of Figures

Alnylam Pharmaceuticals Inc, Performance Chart (2013-2017) 30

Alnylam Pharmaceuticals Inc, Ratio Charts 32

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 33

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 34


List Of Table

List of Tables

Alnylam Pharmaceuticals Inc, Key Facts 6

Alnylam Pharmaceuticals Inc, Key Employees 7

Alnylam Pharmaceuticals Inc, Key Employee Biographies 8

Alnylam Pharmaceuticals Inc, Major Products and Services 9

Alnylam Pharmaceuticals Inc, History 10

Alnylam Pharmaceuticals Inc, Subsidiaries 17

Alnylam Pharmaceuticals Inc, Joint Venture 17

Alnylam Pharmaceuticals Inc, Key Competitors 26

Alnylam Pharmaceuticals Inc, Ratios based on current share price 27

Alnylam Pharmaceuticals Inc, Annual Ratios 28

Alnylam Pharmaceuticals Inc, Annual Ratios (Cont...1) 29

Alnylam Pharmaceuticals Inc, Interim Ratios 31

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 33

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 34

Alnylam Pharmaceuticals Inc, Recent Deals Summary 35

Currency Codes 52

Capital Market Ratios 52

Equity Ratios 53

Profitability Ratios 53

Cost Ratios 54

Liquidity Ratios 54

Leverage Ratios 55

Efficiency Ratios 55

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Alnylam Pharmaceuticals Inc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Sylentis SAU

SOM Biotech SL

Quark Pharmaceuticals Inc

Prothena Corp Plc

Pfizer Inc

Marina Biotech Inc

Ionis Pharmaceuticals Inc

GlaxoSmithKline Plc

Dicerna Pharmaceuticals Inc

Arrowhead Pharmaceuticals Inc